GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Gentian Diagnostics AS (OSL:GENT) » Definitions » Forward PE Ratio

Gentian Diagnostics AS (OSL:GENT) Forward PE Ratio : 28.03 (As of May. 06, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Gentian Diagnostics AS Forward PE Ratio?

Gentian Diagnostics AS's Forward PE Ratio for today is 28.03.

Gentian Diagnostics AS's PE Ratio without NRI for today is 17.39.

Gentian Diagnostics AS's PE Ratio (TTM) for today is 17.39.


Gentian Diagnostics AS Forward PE Ratio Historical Data

The historical data trend for Gentian Diagnostics AS's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gentian Diagnostics AS Forward PE Ratio Chart

Gentian Diagnostics AS Annual Data
Trend 2024-12
Forward PE Ratio
26.67

Gentian Diagnostics AS Quarterly Data
2024-12
Forward PE Ratio 26.67

Competitive Comparison of Gentian Diagnostics AS's Forward PE Ratio

For the Medical Devices subindustry, Gentian Diagnostics AS's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gentian Diagnostics AS's Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gentian Diagnostics AS's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Gentian Diagnostics AS's Forward PE Ratio falls into.


;
;

Gentian Diagnostics AS Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Gentian Diagnostics AS  (OSL:GENT) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Gentian Diagnostics AS Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Gentian Diagnostics AS's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gentian Diagnostics AS Business Description

Traded in Other Exchanges
Address
Bjornasveien 5, Moss, NOR, 1596
Gentian Diagnostics AS operates as a medical diagnostics company in Norway. It develops and produces in-vitro diagnostic reagents (IVD) for use in medical diagnostics and research. Its portfolio and pipeline of reagents span areas of inflammations, severe infections, kidney diseases, heart failures, and veterinary healthcare. The company's product portfolio includes the Gentian Cystatin C Immunoassay, the GCAL circulating calprotectin immunoassay (IVDR), the Gentian Retinol Binding Protein (RBP), and the Gentian Canine CRP among others. Geographically, it generates a majority of its revenue from Europe followed by Asia and the United States of America.

Gentian Diagnostics AS Headlines